Ionis Pharmaceuticals (IONS) Non-Current Assets (2009 - 2026)

Ionis Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $513.0 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 30.2% year-over-year to $513.0 million; the TTM figure through Mar 2026 stood at $2.0 billion (up 30.66% YoY), while the FY2025 annual figure was $533.2 million, up 39.08% from the prior year.
• Non-Current Assets was $513.0 million for Q1 2026 at Ionis Pharmaceuticals, down from $533.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $533.2 million in Q4 2025 to a low of $265.0 million in Q2 2022.
• Historically, Non-Current Assets has averaged $373.5 million across 5 years, with a median of $354.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets rose 1.65% in 2024, then soared 39.99% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $331.2 million in 2022, then advanced by 5.14% to $348.2 million in 2023, then increased by 10.1% to $383.4 million in 2024, then surged by 39.08% to $533.2 million in 2025, then fell by 3.78% to $513.0 million in 2026.
• The last three Non-Current Assets figures came in at $513.0 million (Q1 2026), $533.2 million (Q4 2025), and $514.1 million (Q3 2025), per Business Quant data.